secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2023-06-23T23:59:59+00:00
Accession:  0001437749-23-018173
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa receives Nasdaq non-compliance notice for independent director majority rule
--------------------------------------------------------------------------------

- Received notice on June 21, 2023 for failing Nasdaq Listing Rule 5605(b)(1) requiring majority independent directors.
- Non-compliance triggered by appointment of Greg Weaver as EVP/CFO; he was previously an independent director.
- No immediate delisting effect; common stock continues trading on Nasdaq pending compliance process.
- Company has until June 1, 2024 or next annual meeting to regain compliance; intends to adjust board composition.
- If not regained, Staff may delist; Company can appeal to a Nasdaq Hearings Panel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000143774923018173/0001437749-23-018173-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000143774923018173/atos20230622_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-018173

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer